Mergers and Acquisitions

AGC Biologics Acquires Cell and Gene Therapy Commercial Manufacturing Facility

August 09, 2021

AGC Biologics has acquired Novartis’ Longmont, Colorado, manufacturing facility for the commercial production of cell and gene therapies.

Evonik Expands Biomaterials Portfolio through JeNaCell Acquisition

August 05, 2021

Evonik has acquired the German biotech company JeNaCell, expanding its biomaterials portfolio.

WuXi STA Finalizes Acquisition of BMS’ Swiss Manufacturing Facility

August 05, 2021

WuXi STA has finalized its acquisition of Bristol Myers Squibb’s drug product manufacturing facility based in Couvet, Switzerland.

PerkinElmer to Acquire BioLegend in $5.25-Billion Deal

July 27, 2021

PerkinElmer has entered into an agreement to acquire BioLegend, a global developer and manufacturer, in a deal valued at $5.25 billion.

BioNTech to Acquire Kite’s TCR Cell Therapy Platform and Manufacturing Facility

July 21, 2021

BioNTech will acquire a TCR cell therapy R&D platform as well as a manufacturing facility in Gaithersburg, Md., from Kite, a Gilead company.

MorphoSys to Complete $1.7 Billion Acquisition of Constellation Pharmaceuticals

July 16, 2021

MorphoSys completes the acquisition of Constellation, a clinical-stage biopharmaceutical company.

Lilly Acquires Protomer Technologies in Potential $1-Billion Deal

July 14, 2021

Eli Lilly and Company has announced its acquisition of biotech firm Protomer Technologies, giving it a protein-engineering platform for next-generation protein therapeutics.

Cytiva Acquires Intermountain Life Sciences

July 01, 2021

The acquisition of Intermountain Life Sciences will double Cytiva’s capacity for buffers and liquid cell culture media at its manufacturing site in Logan, Utah.

AbbVie to Acquire TeneoOne and Lead Asset for Multiple Myeloma Treatment

June 25, 2021

AbbVie has exercised its right to acquire TeneoOne, along with its lead immunotherapeutic asset for the potential treatment of multiple myeloma.

Exscientia Enters Binding Agreement to Acquire Allcyte

June 21, 2021

Exscientia has entered into a binding agreement to acquire the artificial intelligence precision-based medicines company, Allcyte.